Skip to content
10-Q

Quarterly Report

Amylyx Pharmaceuticals, Inc. AMLX

0001193125-26-210292

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 111.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 110.56M sh
Shares Diluted Q1 2026 · Mar 31, 2025 85.7M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$36.88M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$39.82M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $229.14M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $226.65M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $59.76M
Stockholders Equity Q1 2026 · Mar 31, 2026 $273.16M
Stockholders Equity Q1 2026 · Dec 31, 2025 $305.26M
Stockholders Equity Q1 2026 · Mar 31, 2025 $201.42M
Stockholders Equity Q1 2026 · Dec 31, 2024 $164.77M
Current Liabilities Q1 2026 · Mar 31, 2026 $15.97M
Current Liabilities Q1 2026 · Dec 31, 2025 $22.69M
Total Liabilities Q1 2026 · Mar 31, 2026 $20.44M
Total Liabilities Q1 2026 · Dec 31, 2025 $27.39M
Current Assets Q1 2026 · Mar 31, 2026 $285.02M
Current Assets Q1 2026 · Dec 31, 2025 $323.67M
Total Assets Q1 2026 · Mar 31, 2026 $293.6M
Total Assets Q1 2026 · Dec 31, 2025 $332.65M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.37
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.42
Eps Basic Q1 2026 · Mar 31, 2026 −$0.37
Eps Basic Q1 2026 · Mar 31, 2025 −$0.42
Sga Expense Q1 2026 · Mar 31, 2026 $16.17M
Sga Expense Q1 2026 · Mar 31, 2025 $15.68M
Rd Expense Q1 2026 · Mar 31, 2026 $27.61M
Rd Expense Q1 2026 · Mar 31, 2025 $22.12M
Net Income Q1 2026 · Mar 31, 2026 −$41.28M
Net Income Q1 2026 · Mar 31, 2025 −$35.91M
Operating Income Q1 2026 · Mar 31, 2026 −$43.78M
Operating Income Q1 2026 · Mar 31, 2025 −$37.8M
Capex Q1 2026 · Mar 31, 2025 $11K